Pfiz­er chips in on $26M raise for rheuma­toid arthri­tis col­lab­o­ra­tor; Han­soh li­cens­es an an­ti-fun­gal for a mys­te­ri­ous in­fec­tion

Two weeks af­ter Pfiz­er jumped in­to an R&D part­ner­ship with Im­cyse, the Bel­gian biotech re­ports that the phar­ma gi­ant has helped con­tribute to a new, $26 mil­lion add-on raise to their B round.

Im­cyse re­ports Wednes­day morn­ing that the added cash will go to help fund its work on a pipeline of im­munother­a­pies. Biogeno­sis, Epimede, LSP, Noshaq, So­ciété Ré­gionale d’In­vestisse­ment de Wal­lonie (SRIW), So­ciété Fédérale de Par­tic­i­pa­tions et d’In­vestisse­ment (SF­PI) and KU Leu­ven all par­tic­i­pat­ed.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.